title: Porphyrin-related photosensitizers for cancer imaging and therapeutic applications.
abstract: A photosensitizer is defined as a chemical entity, which upon absorption of light induces a chemical or physical alteration of another chemical entity. Some photosensitizers are utilized therapeutically such as in photodynamic therapy (PDT) and for diagnosis of cancer (fluorescence diagnosis, FD). PDT is approved for several cancer indications and FD has recently been approved for diagnosis of bladder cancer. The photosensitizers used are in most cases based on the porphyrin structure. These photosensitizers generally accumulate in cancer tissues to a higher extent than in the surrounding tissues and their fluorescing properties may be utilized for cancer detection. The photosensitizers may be chemically synthesized or induced endogenously by an intermediate in heme synthesis, 5-aminolevulinic acid (5-ALA) or 5-ALA esters. The therapeutic effect is based on the formation of reactive oxygen species (ROS) upon activation of the photosensitizer by light. Singlet oxygen is assumed to be the most important ROS for the therapeutic outcome. The fluorescing properties of the photosensitizers can be used to evaluate their intracellular localization and treatment effects. Some photosensitizers localize intracellularly in endocytic vesicles and upon light exposure induce a release of the contents of these vesicles, including externally added macromolecules, into the cytosol. This is the basis for a novel method for macromolecule activation, named photochemical internalization (PCI). PCI has been shown to potentiate the biological activity of a large variety of macromolecules and other molecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins, immunotoxins, gene-encoding plasmids, adenovirus, peptide-nucleic acids and the chemotherapeutic drug bleomycin. The background and present status of PDT, FD and PCI are reviewed.
authors.affiliation: Department of Radiation Biology, The Norwegian Radium Hospital, Oslo, Norway. kristian.ebrg@labmed.uio.no
authors.forename: K
authors.initials: K
authors.lastname: Berg
authors.forename: P K
authors.initials: PK
authors.lastname: Selbo
authors.forename: A
authors.initials: A
authors.lastname: Weyergang
authors.forename: A
authors.initials: A
authors.lastname: Dietze
authors.forename: L
authors.initials: L
authors.lastname: Prasmickaite
authors.forename: A
authors.initials: A
authors.lastname: Bonsted
authors.forename: B Ø
authors.initials: BØ
authors.lastname: Engesaeter
authors.forename: E
authors.initials: E
authors.lastname: Angell-Petersen
authors.forename: T
authors.initials: T
authors.lastname: Warloe
authors.forename: N
authors.initials: N
authors.lastname: Frandsen
authors.forename: A
authors.initials: A
authors.lastname: Høgset
mesh_terms: D000818:Animals; D005453:Fluorescence; D006801:Humans; D046911:Macromolecular Substances; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis / Q000628:therapy; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use
chemical_list: D046911:Macromolecular Substances; D017319:Photosensitizing Agents; D011166:Porphyrins